CEO SUMMARY: Non-payment of molecular test claims for the first five months of 2013 is not the only financial disruption for labs that perform these tests. Reports are coming in about how Medicare contractors, Medicaid programs, and private payers are declining to pay claims based on rulings that the molecular tests fail to meet medical […]
Labs Face Consequences from MolDx Test ‘Mess’
Decisions threaten laboratory viability and steady progress toward personalized medicine
- By Joseph Burns
- > From the Volume XX No. 8 - June 17, 2013 Issue
- Tags: cap, cpt, cpt code, dark report, diagnostic testing, Diagnostic tests, lab billing, lab leader, lab test, lab tests, laboratories, laboratory company, laboratory organization, laboratory organizations, medical records, Medicare, Medicare Administrative Contractor, Medicare Part B, molecular assay, molecular assays, molecular diagnostic, molecular diagnostic test, molecular diagnostic testing, molecular diagnostic tests, molecular testing, molecular tests, mopath, personalized medicine, private payer, the dark report, the laboratory
